Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.

NCT00516373 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00516373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00516373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
July 11, 2005
Completion date
April 26, 2023
Enrollment
98 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

brca1 protein, brca2 protein, ovarian neoplasms